Anixa Biosciences, Inc.

Report azionario NasdaqCM:ANIX

Capitalizzazione di mercato: US$92.2m

Anixa Biosciences Gestione

Criteri Gestione verificati 3/4

Anixa Biosciences Il CEO è Amit Kumar, nominato in Jul2017, e ha un mandato di 8.83 anni. la retribuzione annua totale è $ 2.55M, composta da 32% di stipendio e 68% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.82% delle azioni della società, per un valore di $ 1.68M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 8.8 anni e 7.6 anni.

Informazioni chiave

Amit Kumar

Amministratore delegato

US$2.5m

Compenso totale

Percentuale dello stipendio del CEO32.01%
Mandato del CEO8.8yrs
Proprietà del CEO1.8%
Durata media del management8.8yrs
Durata media del Consiglio di amministrazione7.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi • Mar 25

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Dec 19

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 40%?

Key Insights The projected fair value for Anixa Biosciences is US$4.21 based on 2 Stage Free Cash Flow to Equity Anixa...
Articolo di analisi • Sep 12

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Articolo di analisi • May 23

We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Articolo di analisi • Jan 19

We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Articolo di analisi • Oct 06

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Articolo di analisi • Apr 27

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Key Insights The projected fair value for Anixa Biosciences is US$7.24 based on 2 Stage Free Cash Flow to Equity Anixa...
Articolo di analisi • Jan 13

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Anixa Biosciences...
Articolo di analisi • Sep 26

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Aug 15

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

The shares of clinical-stage biotech Anixa Biosciences (NASDAQ:ANIX) jumped ~11% to reach the highest level since November on the announcement that the first patient received its chimeric antigen receptor T-cell (CAR-T) therapy in a Phase 1 clinical trial for ovarian cancer.   The dose escalation study conducted with its partner Moffitt Cancer Center is designed to assess the early efficacy data, safety and maximum tolerated dose of the follicle-stimulating hormone receptor T-cells. The trial is expected to enroll up to 48 patients at the Moffitt Cancer Center. Anixa’s (ANIX) CAR-T approach used in the study is known as chimeric endocrine receptor T-cell (CER-T) therapy. It differs from traditional CAR-T drugs in that it specifically targets the follicle-stimulating hormone receptor (FSHR) which, according to research, is exclusively located in ovarian cells of healthy adult women. In March, Anixa (ANIX) announced initial plans to conduct the trial.
Seeking Alpha • Jul 21

Anixa to get additional US patent linked to breast cancer vaccine technology

Anixa Biosciences (NASDAQ:ANIX) said the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent related to the company's breast cancer vaccine technology. The company said the technology has been exclusively licensed from and is being developed in partnership with Cleveland Clinic. The patent is titled 'Breast Cancer Vaccine' and the lead inventor is Vincent Tuohy of the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. "This breast cancer vaccine has the potential to prevent Triple Negative Breast Cancer ("TNBC"), the deadliest form of breast cancer, and perhaps other forms of breast cancer that express alpha-lactalbumin," said Anixa Chairman and CEO Amit Kumar.
Articolo di analisi • Jun 13

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • May 11

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June. While the biotech sector has been suffering large losses over the past month, Anixa Biosciences shares have moved up remarkably. Trial enrollment for the vaccine trial was fast, and the company seems optimistic about the near-term future of the company. The market is huge, and if the trial is successful, chances are we are seeing the beginning of a huge spike in share price. 2022 will, in any case, be the year for Anixa, with other programs ongoing as well.
Articolo di analisi • Feb 24

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Oct 28

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. By way of example, Anixa Biosciences...
Seeking Alpha • Sep 23

Our First Look At Anixa Biosciences

Today, we take an in-depth look at Anixa Biosciences, a small developmental firm on the west coast. The company's pipeline has multiple 'shots on goal' including one candidate that has shown some early analytical potential promise against the Covid-19 Delta variant. A full analysis is provided in the paragraphs below.
Articolo di analisi • Jun 12

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Articolo di analisi • Jan 13

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Amit Kumar rispetto agli utili di Anixa Biosciences?
DataCompenso totaleStipendioUtili della società
Jan 31 2026n/an/a

-US$10m

Oct 31 2025US$3mUS$815k

-US$11m

Jul 31 2025n/an/a

-US$11m

Apr 30 2025n/an/a

-US$12m

Jan 31 2025n/an/a

-US$12m

Oct 31 2024US$3mUS$785k

-US$13m

Jul 31 2024n/an/a

-US$12m

Apr 30 2024n/an/a

-US$12m

Jan 31 2024n/an/a

-US$11m

Oct 31 2023US$4mUS$720k

-US$10m

Jul 31 2023n/an/a

-US$11m

Apr 30 2023n/an/a

-US$11m

Jan 31 2023n/an/a

-US$12m

Oct 31 2022US$2mUS$631k

-US$14m

Jul 31 2022n/an/a

-US$14m

Apr 30 2022n/an/a

-US$16m

Jan 31 2022n/an/a

-US$15m

Oct 31 2021US$11mUS$573k

-US$13m

Jul 31 2021n/an/a

-US$11m

Apr 30 2021n/an/a

-US$9m

Jan 31 2021n/an/a

-US$10m

Oct 31 2020US$2mUS$522k

-US$10m

Jul 31 2020n/an/a

-US$10m

Apr 30 2020n/an/a

-US$9m

Jan 31 2020n/an/a

-US$9m

Oct 31 2019US$665kUS$476k

-US$12m

Compensazione vs Mercato: La retribuzione totale di Amit ($USD 2.55M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 630.36K ).

Compensazione vs guadagni: La retribuzione di Amit è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Amit Kumar (61 yo)

8.8yrs
Mandato
US$2,546,684
Compensazione

Dr. Amit Kumar, Ph.D. was a Director at Ascent Solar Technologies, Inc. since June 2007 until September 16, 2022 and had been its Independent Chairman of the Board since January 2011 until September 16, 20...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Amit Kumar
CEO, Chairman & Co-Chair of CBAB8.8yrsUS$2.55m1.82%
$ 1.7m
Michael Catelani
President9.5yrsUS$1.30m0.13%
$ 122.4k
Pamela Garzone
Chief Development Officer & Chair Breast Cancer Clinical Advisory Board4.7yrsNessun datoNessun dato
8.8yrs
Durata media
61yo
Età media

Gestione esperta: Il team dirigenziale di ANIX è esperto e expertise (durata media dell'incarico 8.8 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Amit Kumar
CEO, Chairman & Co-Chair of CBAB13.5yrsUS$2.55m1.82%
$ 1.7m
Pamela Garzone
Chief Development Officer & Chair Breast Cancer Clinical Advisory Board3.3yrsNessun datoNessun dato
Lewis Titterton
Lead Independent Director8.8yrsUS$134.63k2.89%
$ 2.7m
H. Shepard
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Linda Kelley
Member of Scientific Advisory Board7.6yrsNessun datoNessun dato
Ian Frazer
Member of Scientific Advisory Board6.6yrsNessun datoNessun dato
G. Budd
Member of Breast Cancer Clinical Advisory Board3.3yrsNessun datoNessun dato
Arnold Baskies
Member of SAB & Breast Cancer Clinical Advisory Board7.7yrsUS$134.63k0.40%
$ 371.2k
Marco Davila
Member of Scientific Advisory Board7.6yrsNessun datoNessun dato
Jose Conejo-Garcia
Member of Scientific Advisory Board7.6yrsNessun datoNessun dato
Daniel Abate-Daga
Member of Scientific Advisory Board7.6yrsNessun datoNessun dato
Emily Gottschalk
Independent Director6.6yrsUS$134.63k0.14%
$ 125.6k
7.6yrs
Durata media
72yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ANIX sono considerati esperti (durata media dell'incarico 7.6 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/22 10:58
Prezzo dell'azione a fine giornata2026/05/22 00:00
Utili2026/01/31
Utili annuali2025/10/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Anixa Biosciences, Inc. è coperta da 6 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Andrew D'SilvaB. Riley Securities, Inc.
Jason KolbertD. Boral Capital LLC.
Ilya ZubkovFreedom Broker